LGALS1 and ovarian carcinoma: Moreover, Gal-1 overexpression could significantly decrease the sensitivities of ovarian cancer cells to cisplatin, illustrating a possible explanation for decreased survival of ovarian cancer patients with increased Gal-1 expression [14].